183 related articles for article (PubMed ID: 16639080)
1. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance.
Chabalier C; Lamare C; Racca C; Privat M; Valette A; Larminat F
Cell Cycle; 2006 May; 5(9):1001-7. PubMed ID: 16639080
[TBL] [Abstract][Full Text] [Related]
2. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
[TBL] [Abstract][Full Text] [Related]
3. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint.
Sudo T; Nitta M; Saya H; Ueno NT
Cancer Res; 2004 Apr; 64(7):2502-8. PubMed ID: 15059905
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 is regulated by Chk2 in response to spindle damage.
Chabalier-Taste C; Racca C; Dozier C; Larminat F
Biochim Biophys Acta; 2008 Dec; 1783(12):2223-33. PubMed ID: 18804494
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
Promkan M; Liu G; Patmasiriwat P; Chakrabarty S
Int J Cancer; 2009 Dec; 125(12):2820-8. PubMed ID: 19551867
[TBL] [Abstract][Full Text] [Related]
6. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
7. Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer.
Chong T; Sarac A; Yao CQ; Liao L; Lyttle N; Boutros PC; Bartlett JMS; Spears M
J Ovarian Res; 2018 Apr; 11(1):27. PubMed ID: 29618387
[TBL] [Abstract][Full Text] [Related]
8. Caspase-mediated specific cleavage of BubR1 is a determinant of mitotic progression.
Kim M; Murphy K; Liu F; Parker SE; Dowling ML; Baff W; Kao GD
Mol Cell Biol; 2005 Nov; 25(21):9232-48. PubMed ID: 16227576
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells.
Lee EA; Keutmann MK; Dowling ML; Harris E; Chan G; Kao GD
Mol Cancer Ther; 2004 Jun; 3(6):661-9. PubMed ID: 15210851
[TBL] [Abstract][Full Text] [Related]
10. Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.
Dowling M; Voong KR; Kim M; Keutmann MK; Harris E; Kao GD
Cancer Biol Ther; 2005 Feb; 4(2):197-206. PubMed ID: 15753652
[TBL] [Abstract][Full Text] [Related]
11. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy.
Rodrigues-Ferreira S; Nehlig A; Moindjie H; Monchecourt C; Seiler C; Marangoni E; Chateau-Joubert S; Dujaric ME; Servant N; Asselain B; de Cremoux P; Lacroix-Triki M; Arnedos M; Pierga JY; André F; Nahmias C
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23691-23697. PubMed ID: 31685623
[TBL] [Abstract][Full Text] [Related]
12. Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro.
Prencipe M; Fitzpatrick P; Gorman S; Tosetto M; Klinger R; Furlong F; Harrison M; O'Connor D; Roninson IB; O'Sullivan J; McCann A
Br J Cancer; 2009 Dec; 101(11):1900-8. PubMed ID: 19935801
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability.
Yuan B; Xu Y; Woo JH; Wang Y; Bae YK; Yoon DS; Wersto RP; Tully E; Wilsbach K; Gabrielson E
Clin Cancer Res; 2006 Jan; 12(2):405-10. PubMed ID: 16428479
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.
Chin GM; Herbst R
Mol Cancer Ther; 2006 Oct; 5(10):2580-91. PubMed ID: 17041103
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel.
Zhao W; Song Y; Xu B; Zhan Q
Cancer Biol Ther; 2012 Feb; 13(3):156-63. PubMed ID: 22353935
[TBL] [Abstract][Full Text] [Related]
16. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.
Swanton C; Marani M; Pardo O; Warne PH; Kelly G; Sahai E; Elustondo F; Chang J; Temple J; Ahmed AA; Brenton JD; Downward J; Nicke B
Cancer Cell; 2007 Jun; 11(6):498-512. PubMed ID: 17560332
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 regulates gene expression for orderly mitotic progression.
Bae I; Rih JK; Kim HJ; Kang HJ; Haddad B; Kirilyuk A; Fan S; Avantaggiati ML; Rosen EM
Cell Cycle; 2005 Nov; 4(11):1641-66. PubMed ID: 16258266
[TBL] [Abstract][Full Text] [Related]
19. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.
Yan Y; Spieker RS; Kim M; Stoeger SM; Cowan KH
Oncogene; 2005 May; 24(20):3285-96. PubMed ID: 15735702
[TBL] [Abstract][Full Text] [Related]
20. G2 cell cycle arrest, down-regulation of cyclin B, and induction of mitotic catastrophe by the flavoprotein inhibitor diphenyleneiodonium.
Scaife RM
Mol Cancer Ther; 2004 Oct; 3(10):1229-37. PubMed ID: 15486190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
